Access our Data Analysis Report for Oncology

Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway are able to produce anti-tumourigenic effects in a variety of cancers. Evidence suggests that susceptibility to anti-PD-L1 agents is dependent on a tumour’s immunological phenotype. Checkpoint blockade by anti-PD-L1 agents depends on the presence of immune cells to act upon. Prior to the publication of our collaborative TGFβ1 attenuated tumour response to PD-L1 blockade by contributing to exclusion of T cells study, this was uncharacterised in metastatic urothelial carcinomas (mUCs).

The aim of this analysis was to identify biomarkers associated with response to treatment and survival and to investigate the relationship between immunological phenotype and response.

Fios Difference

Fios Genomics offers established, cost-efficient and rapid turnaround analysis services for gene expression data from a range of platforms.

Every time our clients work with Fios, they benefit from:  

• A dedicated analyst backed by an experienced team to curate all data, identify the most appropriate statistical approach to take, and provide a biological interpretation of results. 
• An interactive data analysis report, internally peer-reviewed, including all analysis methods and results.  
• Post-report follow-ups: upon receipt of our data analysis report, we arrange a teleconference so that our lead analyst can talk through the results. 
• Access to large capacity computing and secure data storage facilities. 

Fill out this form to access our

data analysis sample report